Cécile Pagès

1.9k total citations
53 papers, 1.1k citations indexed

About

Cécile Pagès is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Cécile Pagès has authored 53 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 23 papers in Molecular Biology and 13 papers in Immunology. Recurrent topics in Cécile Pagès's work include Cancer Immunotherapy and Biomarkers (19 papers), Melanoma and MAPK Pathways (19 papers) and CAR-T cell therapy research (14 papers). Cécile Pagès is often cited by papers focused on Cancer Immunotherapy and Biomarkers (19 papers), Melanoma and MAPK Pathways (19 papers) and CAR-T cell therapy research (14 papers). Cécile Pagès collaborates with scholars based in France, United States and Italy. Cécile Pagès's co-authors include Célèste Lebbé, M. Bagot, Barouyr Baroudjian, Maxime Battistella, M. Viguier, Matthieu Allez, Philippe Bertheau, Nicole Basset‐Séguin, Samia Mourah and Laëtitia Vercellino and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Cécile Pagès

49 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cécile Pagès France 19 794 302 232 190 188 53 1.1k
Suthee Rapisuwon United States 11 683 0.9× 329 1.1× 246 1.1× 158 0.8× 81 0.4× 30 997
Inna M. Chen Denmark 16 583 0.7× 171 0.6× 161 0.7× 148 0.8× 68 0.4× 53 839
Shogo Kumagai Japan 15 450 0.6× 216 0.7× 254 1.1× 389 2.0× 177 0.9× 37 1.0k
Yanina Jansen Belgium 15 595 0.7× 345 1.1× 192 0.8× 156 0.8× 88 0.5× 48 887
L. Peuvrel France 19 493 0.6× 280 0.9× 152 0.7× 146 0.8× 186 1.0× 63 853
Marzia Locatelli Italy 17 757 1.0× 329 1.1× 151 0.7× 221 1.2× 79 0.4× 36 1.2k
Hirohisa Hirabayashi Japan 13 462 0.6× 339 1.1× 191 0.8× 219 1.2× 88 0.5× 28 979
David Z. Chang United States 14 776 1.0× 339 1.1× 357 1.5× 116 0.6× 500 2.7× 19 1.3k
Lorenza Di Guardo Italy 15 987 1.2× 360 1.2× 398 1.7× 248 1.3× 75 0.4× 48 1.2k
Marta Santisteban Spain 16 582 0.7× 308 1.0× 161 0.7× 134 0.7× 78 0.4× 55 957

Countries citing papers authored by Cécile Pagès

Since Specialization
Citations

This map shows the geographic impact of Cécile Pagès's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cécile Pagès with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cécile Pagès more than expected).

Fields of papers citing papers by Cécile Pagès

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cécile Pagès. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cécile Pagès. The network helps show where Cécile Pagès may publish in the future.

Co-authorship network of co-authors of Cécile Pagès

This figure shows the co-authorship network connecting the top 25 collaborators of Cécile Pagès. A scholar is included among the top collaborators of Cécile Pagès based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cécile Pagès. Cécile Pagès is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pagès, Cécile, et al.. (2025). Rare Immuno-Induced Keratoacanthomas Showed on 18F-FDG PET/CT in a Metastatic Melanoma Patient. Clinical Nuclear Medicine. 50(5). e288–e289. 1 indexed citations
2.
Lusque, Amélie, Stéphanie Brayer, Thomas Filleron, et al.. (2025). TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study. International Journal of Cancer. 157(3). 534–548.
3.
4.
Mortier, Laurent, Stéphane Dalle, O. Dereure, et al.. (2024). When to stop immunotherapy for advanced melanoma: Emulation of target trials.. Journal of Clinical Oncology. 42(16_suppl). 9521–9521.
5.
Sibaud, V., Cécile Pagès, K. Delavigne, et al.. (2024). Revue des atteintes dermatologiques atypiques et/ou systémiques en lien avec les inhibiteurs de checkpoints immunologiques. La Revue de Médecine Interne. 46(7). 369–376. 1 indexed citations
6.
Nardin, Charlée, Célèste Lebbé, Cécile Pagès, et al.. (2024). Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).. Journal of Clinical Oncology. 42(16_suppl). 9578–9578.
7.
Montfort, Anne, Thomas Filleron, Cécile Pagès, et al.. (2020). Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial. Clinical Cancer Research. 27(4). 1037–1047. 70 indexed citations
8.
Pagès, Cécile, Léonor Chaltiel, V. Sibaud, et al.. (2020). Survival estimation of melanoma patients with brain metastasis using the Melanoma-molGPA score: external validation from a French cohort. Melanoma Research. 30(5). 472–476. 3 indexed citations
9.
Sibaud, V., É. Tournier, Laurence Lamant, et al.. (2019). Multiple Keratoacanthoma-like Lesions in a Patient Treated with Pembrolizumab. Acta Dermato Venereologica. 99(13). 1201–1302. 8 indexed citations
10.
Boulinguez, S., et al.. (2019). Advanced Cutaneous Squamous Cell Carcinoma Is Associated with Suboptimal Initial Management in a Cohort of 109 Patients. Dermatology. 235(6). 516–521. 6 indexed citations
11.
Gauci, Marie-Léa, Barouyr Baroudjian, Pauline Laly, et al.. (2017). Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab. Seminars in Arthritis and Rheumatism. 47(2). 281–287. 34 indexed citations
12.
Gauci, Marie-Léa, Pauline Laly, Tiphaine Vidal-Trécan, et al.. (2017). Autoimmune diabetes induced by PD-1 inhibitor—retrospective analysis and pathogenesis: a case report and literature review. Cancer Immunology Immunotherapy. 66(11). 1399–1410. 101 indexed citations
13.
Louveau, Baptiste, Jörg Tost, Florence Mauger, et al.. (2017). Clinical value of early detection of circulating tumour DNA-BRAFV600mut in patients with metastatic melanoma treated with a BRAF inhibitor. ESMO Open. 2(2). e000173–e000173. 6 indexed citations
14.
Lambert, Jérôme, Marie Roelens, E. Maubec, et al.. (2016). Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response. OncoImmunology. 5(7). 1136045–1136045. 18 indexed citations
15.
Cassinat, Bruno, Raphaël Porcher, Marie‐Hélène Schlageter, et al.. (2016). Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy. International Immunopharmacology. 40. 466–473. 27 indexed citations
16.
Bohelay, G., Maxime Battistella, Cécile Pagès, et al.. (2015). Ultrasound-guided core needle biopsy of superficial lymph nodes. Melanoma Research. 25(6). 519–527. 11 indexed citations
17.
Chasset, François, Cécile Pagès, Lucie Biard, et al.. (2015). Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids. European Journal of Dermatology. 25(1). 36–44. 35 indexed citations
18.
Danlos, François‐Xavier, Cécile Pagès, J. Roux, et al.. (2014). Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma. Melanoma Research. 25(2). 178–179. 11 indexed citations
19.
Pagès, Cécile, Pierre Schneider, M. Viguier, et al.. (2013). Vemurafenib in the French temporary authorization for use metastatic melanoma cohort. Melanoma Research. 24(1). 75–82. 15 indexed citations
20.
Dupuy, Stéphanie, Marion Lambert, David Zucman, et al.. (2012). Human Herpesvirus 8 (HHV8) Sequentially Shapes the NK Cell Repertoire during the Course of Asymptomatic Infection and Kaposi Sarcoma. PLoS Pathogens. 8(1). e1002486–e1002486. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Suthee Rapisuwon Breakdown of academic impact, for papers by Inna M. Chen Breakdown of academic impact, for papers by Shogo Kumagai Breakdown of academic impact, for papers by Yanina Jansen Breakdown of academic impact, for papers by L. Peuvrel Breakdown of academic impact, for papers by Marzia Locatelli Breakdown of academic impact, for papers by Hirohisa Hirabayashi Breakdown of academic impact, for papers by David Z. Chang Breakdown of academic impact, for papers by Lorenza Di Guardo Breakdown of academic impact, for papers by Marta Santisteban
Rankless by CCL
2026